MUC16 and cancer: Siglec-9 is expressed on the surface of B-cells, granulocytes and NK cells, and its interaction with membrane-bound MUC16 may pose a barrier to NK cell interaction with cancer cells, while interaction with soluble MUC16 downregulates the activating Fc-γ receptor CD16 on NK cells [194].